- Home
- PRLD
as of 11-28-2025 12:56pm EST
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 69.1M | IPO Year: | 2020 |
| Target Price: | $4.00 | AVG Volume (30 days): | 3.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.61 - $4.22 | Next Earning Date: | 11-12-2025 |
| Revenue: | $10,500,000 | Revenue Growth: | 250.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered PRLD Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare PRLD vs Leading Stocks
See how PRLD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PRLD Prelude Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.